scPharmaceuticals Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2017 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
scPharmaceuticals Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2017 to Q4 2024.
  • scPharmaceuticals Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was -$18.8M, a 36.4% decline year-over-year.
  • scPharmaceuticals Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was -$85.1M, a 55.4% decline year-over-year.
  • scPharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$85.1M, a 55.4% decline from 2023.
  • scPharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$54.8M, a 48.8% decline from 2022.
  • scPharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$36.8M, a 31.4% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 -$85.1M -$18.8M -$5.03M -36.4% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-19
Q3 2024 -$80.1M -$35.1M -$19.5M -125% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$60.6M -$17.1M -$2.94M -20.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$57.7M -$14.1M -$2.9M -25.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$54.8M -$13.8M -$4.56M -49.4% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-19
Q3 2023 -$50.2M -$15.6M -$5.47M -53.8% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$44.8M -$14.2M -$4.46M -46% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$40.3M -$11.2M -$3.48M -45% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$36.8M -$9.25M -$1.93M -26.4% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-13
Q3 2022 -$34.9M -$10.2M -$3.61M -55.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$31.3M -$9.7M -$2.64M -37.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$28.7M -$7.73M -$629K -8.86% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 -$28M -$7.32M +$466K +5.99% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-22
Q3 2021 -$28.5M -$6.55M +$2.49M +27.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$31M -$7.06M +$1.23M +14.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$32.2M -$7.1M -$10K -0.14% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$32.2M -$7.78M +$3.03M +28% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-22
Q3 2020 -$35.2M -$9.04M -$2.83M -45.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$32.4M -$8.3M -$1.04M -14.3% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 -$31.4M -$7.09M +$1.63M +18.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12
Q4 2019 -$33M -$10.8M -$5.72M -112% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-23
Q3 2019 -$27.3M -$6.21M -$446K -7.74% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 -$26.8M -$7.26M +$2.6M +26.3% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 -$29.4M -$8.72M +$13K +0.15% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q4 2018 -$29.4M -$5.1M +$1.78M +25.9% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-24
Q3 2018 -$31.2M -$5.76M -$272K -4.96% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$31M -$9.85M -$3.31M -50.7% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 -$27.6M -$8.73M -$3.82M -77.8% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q4 2017 -$23.8M -$6.88M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-21
Q3 2017 -$5.49M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 -$6.54M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
Q1 2017 -$4.91M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.